Google
×
Conclusion: This study suggests that the level of Aβ38 can potentially contribute in the diagnostic distinction between AD and DLB when combined with Aβ42. Single measures had low diagnostic accuracy, suggesting that developing a panel of markers is the most promising strategy.
Nov 3, 2010
May 3, 2011 · The clinical distinction between Alzheimer's disease (AD) and dementia with Lewy bodies. (DLB) is sometimes difficult, particularly in mild ...
Dive into the research topics of 'CSF amyloid beta 38 as a novel diagnostic marker for dementia with Lewy bodies'. Together they form a unique fingerprint.
People also ask
This study suggests that the level of Aβ38 can potentially contribute in the diagnostic distinction between AD and DLB when combined with Aβ42. Single measures ...
Oct 10, 2019 · The main finding of this study is lower CSF levels of Aβ42, Aβ40, and Aβ38 peptides in a large group of DLB patients compared with controls, ...
The present study is the first attempt to evaluate the meaning of Aβ peptide patterns in CSF for differential diagnosis of the three neurodegenerative diseases.
Jun 18, 2020 · Here, we aimed to identify novel CSF biomarkers for DLB using a high-throughput proteomic approach.
CSF amyloid beta 38 as a novel diagnostic marker for dementia with Lewy bodies. Mark. Mulugeta, Ezra ; Londos, Elisabet LU ; Ballard, Clive ; Alves, Guido ...
Three biomarkers have been well-established and validated internationally to diagnose AD in CSF with ELISAs: β-amyloid(1–42) [Aβ(1–42)], total tau and phospho- ...
May 8, 2020 · Moreover, CSF Aβ42/Aβ38 ratio might be helpful in the differentiation between AD and dementia with Lewy bodies (DLB) [76] and other non-AD ...